NCT02775227View on ClinicalTrials.gov

HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications

PHASE4Active, not recruitingINTERVENTIONAL

Enrollment

126

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

January 31, 2019

Study Completion Date

December 31, 2029

Conditions

Pancreatic FistulaPancreatic Neoplasms

Interventions

DRUG

Hydrocortisone

DRUG

Pasireotide

Trial Locations (1)

Unknown

Helsinki University Central Hospital, Helsinki

All Listed Sponsors

lead

Helsinki University Central Hospital

OTHER